SRR1328035
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INFLAMMATORY_RESPONSE+0.457
- ALLOGRAFT_REJECTION+0.427
- KRAS_SIGNALING_DN+0.427
- IL6_JAK_STAT3_SIGNALING+0.361
- ANGIOGENESIS+0.325
- KRAS_SIGNALING_UP+0.313
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.286
- COAGULATION+0.274
- APICAL_SURFACE+0.253
- COMPLEMENT+0.250
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.738
- MYC_TARGETS_V1-0.585
- DNA_REPAIR-0.537
- UNFOLDED_PROTEIN_RESPONSE-0.524
- MYC_TARGETS_V2-0.514
- ADIPOGENESIS-0.513
- PROTEIN_SECRETION-0.491
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.490
- MTORC1_SIGNALING-0.489
- FATTY_ACID_METABOLISM-0.467
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR615515 | GTEX | — | 0.979 |
| 2 | SRR1487295 | GTEX | — | 0.964 |
| 3 | SRR1475803 | GTEX | — | 0.960 |
| 4 | SRR1443979 | GTEX | — | 0.959 |
| 5 | SRR661433 | GTEX | — | 0.957 |
| 6 | SRR1395951 | GTEX | — | 0.955 |
| 7 | SRR603658 | GTEX | — | 0.955 |
| 8 | SRR1103048 | GTEX | — | 0.954 |
| 9 | SRR1485167 | GTEX | — | 0.953 |
| 10 | SRR1358689 | GTEX | — | 0.952 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INFLAMMATORY_RESPONSE | 0.457 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.427 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.427 | Remibrutinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.361 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.325 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.313 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.286 | Inavolisib | — uncovered |
| COAGULATION | 0.274 | Binimetinib | — uncovered |
| APICAL_SURFACE | 0.253 | Temsirolimus | — uncovered |
| COMPLEMENT | 0.250 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.228 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.168 | Cobimetinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.151 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.130 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.128 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.067 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.027 | Idelalisib | — uncovered |
| MYOGENESIS | 0.023 | Inavolisib | — uncovered |